Caxton Associates LP Moderna, Inc. Transaction History

Caxton Associates LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$135.66 - $197.02 $32.1 Million - $46.7 Million	-236,860 Reduced 98.91%	2,600 $399,000
Q4 2022 Feb 14, 2023	BUY	$118.38 - $210.04 $82,866 - $147,028	700 Added 0.29%	239,460 $43 Million
Q3 2022 Nov 14, 2022	BUY	$118.07 - $194.18 $307,100 - $505,062	2,601 Added 1.1%	238,760 $28.2 Million
Q2 2022 Aug 15, 2022	BUY	$117.13 - $176.59 $7.89 Million - $11.9 Million	67,399 Added 39.94%	236,159 $33.7 Million
Q1 2022 May 16, 2022	BUY	$126.46 - $235.05 $13.2 Million - $24.6 Million	104,600 Added 163.03%	168,760 $29.1 Million
Q4 2021 Feb 14, 2022	SELL	$225.82 - $368.51 $131,201 - $214,104	-581 Reduced 0.9%	64,160 $16.3 Million
Q3 2021 Nov 15, 2021	BUY	$221.9 - $484.47 $13.6 Million - $29.7 Million	61,320 Added 1792.46%	64,741 $24.9 Million
Q2 2021 Aug 16, 2021	SELL	$129.91 - $234.98 $110,943 - $200,672	-854 Reduced 19.98%	3,421 $804,000
Q1 2021 May 17, 2021	BUY	$109.18 - $185.98 $466,744 - $795,064	4,275 New	4,275 $560,000

1,113

241M

9.26M

12.1M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $25.7B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.